SCHEMBL15976016

SCHEMBL15976016

COC(=O)c1cc(Br)nc(-c2ccc(Cl)cc2)c1N=[N+]=[N-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SLC6A3 Q01959 2/20 0.40
SLC6A4 P31645 1/20 0.40
MAP2K4 P45985 1/20 0.39
CNR1 P21554 3/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
PLA2G2A P14555 1/20 0.37
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
ALDH1A1 P00352 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15976000 0.88 TACR3 (0.41) MAPTSMN1; SMN2L3MBTL1SLC6A3PLA2G2A
SCHEMBL15800345 0.87 KDR (0.37) MAPTL3MBTL1RAB9AMAP2K4ALDH1A1
SCHEMBL15976014 0.87 ALDH1A1 (0.38) MAPTSMN1; SMN2L3MBTL1RAB9ASLC6A3
SCHEMBL15976008 0.86 KMO (0.40) MAPTSMN1; SMN2L3MBTL1NPC1RAB9A
SCHEMBL15800330 0.85 CA12 (0.41) MAPTSMN1; SMN2L3MBTL1SLC6A3CA12
SCHEMBL15976018 0.84 PDCD1 (0.39) MAPTSMN1; SMN2L3MBTL1NPC1RAB9A
SCHEMBL15800339 0.81 MAPT (0.41) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL15976013 0.81 MCL1 (0.41) SMN1; SMN2NPC1RAB9ACNR1PLA2G2A
SCHEMBL15976015 0.80 ALDH1A1 (0.34) MAPTSMN1; SMN2L3MBTL1ALDH1A1GAA
SCHEMBL15976011 0.79 KMT2A (0.42) MAPTRAB9AALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
CN-102325752-A Carbazole and carboline kinase inhibitors BRISTOL MYERS SQUIBB CO 2012-01-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 MAPT 4508/4885SMN1; SMN2 3642/4885L3MBTL1 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.